Blood tests after chemoradiotherapy for cervical cancer prognosis
Part of Cancer, Women’s health & pregnancy clinical trials.
This study looks at blood markers—tiny DNA from the blood (cfDNA) and minimal residual disease (MRD)—to better predict outcomes after standard chemoradiotherapy for locally advanced cervical cancer. It may help doctors identify who is more likely to do well and who may need closer follow-up or additional treatment planning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 to 75.
- Have a confirmed diagnosis of cervical cancer on pathology (biopsy).
- Have measurable tumor areas on scans (CT/MRI or PET/CT) before starting treatment.
- Be medically well enough for treatment, such as good energy/fitness scores (ECOG 0–1 or KPS 70–100) and expected survival at least 6 months.
- Have recent blood tests within acceptable ranges (like hemoglobin, white cell count, platelets, liver enzymes, and albumin).
- Not be allergic to rubber products, and have generally normal heart and lung function; also agree to follow the study’s blood testing and follow-up schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of chemotherapy and immunotherapy (pembrolizumab) before surgery works better than standard chemoradiation for locally advanced cervical cancer. It may help shrink tumors more effectively.
This trial tests a new approach for advanced cervical cancer: giving immunotherapy (a drug that helps your immune system fight cancer) before and during standard chemoradiation. The goal is to see if adding immunotherapy can shrink the tumor more and improve outcomes.
This trial tests adding a new immunotherapy drug (cadonilimab) to standard chemotherapy before surgery for locally advanced cervical cancer. The goal is to see if this combination helps shrink the tumor more effectively before surgery.
This study compares two staging methods—using surgery results versus imaging tests—to help doctors plan treatment for locally advanced cervical cancer. It may improve how accurately the cancer is mapped, which could affect treatment choices and outcomes.
This study tests whether a different way of giving standard chemoradiation can lower the risk of blood-related side effects (like low blood cell counts) in people with locally advanced cervical cancer, while still controlling the disease.
This study looks at a simple blood test to help predict how well your tumor will respond to radiation therapy. By measuring a protein called CHI3L1 in your blood before and during treatment, the study aims to help doctors personalize your care.
Hear when a new Locally Advanced Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.